Geubel André P, Sempoux Christine, Rahier Jacques
Department of Gastroenterology, St. Luc University Hospital, Université Catholique de Louvain 10, Avenue Hippocrate, 1200 Brussels, Belgium.
Clin Liver Dis. 2003 May;7(2):295-309. doi: 10.1016/s1089-3261(03)00028-x.
Drug-induced bile duct injury related prolonged or chronic cholestasis is recognized as a common side effect of treatment with several drugs. The severity and duration of the clinical symptoms suggest that this increase in number of reports is not only related to clinician and pathologists being increasingly aware of the condition, but also may represent a true increase in incidence likely related to a time-related growing experience with newer drugs. This clinical presentation encompasses a wide variety of features that may be the source of diagnostic difficulties, especially in the cases where cholestasis occurs days or weeks after the completion of therapy. Even more puzzling is the initial picture of hepatocholangitis, which may be silent and ensuing bile duct paucity with chronic anicteric cholestasis may be another source of diagnostic difficulties in the long-term. These diagnostic difficulties suggest that some of the cases of the so-called "idiopathic adulthood ductopenia" may originate from overlooked drug induced vanishing bile duct syndrome. The pathogenesis of the syndrome remains largely unknown and the determinants of prognosis and outcome. From reproducible data obtained in different studies investigating HLA-dependent predisposition, one may assume that genetics plays a major role even if other unknown additive factors are also likely involved. Severity of initial hepatocholangitis is likely to represent another important determinant of severity and prognosis, however to be assessed in larger longitudinal studies. Therapy of large bile duct injury mimics that of primary sclerosing cholangitis. Treatment of small bile duct injury remains disappointing. Corticosteroids are invariably ineffective. Ursodeoxycholic acid as been shown to induce improvement of clinical and biochemical cholestasis in some selected cases, its efficacy being however unpredictable. Preliminary data about the natural history of the vanishing bile duct syndrome suggest that therapy might be more effective when initiated early.
药物性胆管损伤相关的持续性或慢性胆汁淤积被认为是多种药物治疗的常见副作用。临床症状的严重程度和持续时间表明,报告数量的增加不仅与临床医生和病理学家对该病症的认识日益提高有关,还可能代表发病率的真正上升,这可能与使用新药的时间相关经验增长有关。这种临床表现包含多种特征,可能是诊断困难的根源,尤其是在治疗结束数天或数周后发生胆汁淤积的情况下。更令人困惑的是肝内胆管炎的初始表现,它可能不明显,而随之而来的胆管稀少伴慢性无黄疸胆汁淤积可能是长期诊断困难的另一个根源。这些诊断困难表明,一些所谓的“特发性成人胆管减少症”病例可能源于被忽视的药物性胆管消失综合征。该综合征的发病机制在很大程度上仍然未知,预后和结局的决定因素也不清楚。从不同研究中获得的关于HLA依赖性易感性的可重复数据来看,即使可能还涉及其他未知的附加因素,也可以认为遗传学起主要作用。初始肝内胆管炎的严重程度可能是严重程度和预后的另一个重要决定因素,不过这有待在更大规模的纵向研究中进行评估。大胆管损伤的治疗类似于原发性硬化性胆管炎的治疗。小胆管损伤的治疗仍然令人失望。皮质类固醇总是无效。熊去氧胆酸在一些选定病例中已显示可改善临床和生化胆汁淤积,但其疗效不可预测。关于胆管消失综合征自然史的初步数据表明,早期开始治疗可能更有效。